Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •HIV-1 infection, as documented by a rapid HIV test or any FDA-approved HIV-1 enzyme or chemiluminescence immunoassay (E/CIA) test kit and confirmed by western blot at any time prior to study entry
• •* Documentation may be serologic (positive ELISA and positive western blot), or other federally approved licensed HIV diagnostic test
• •* Prior documentation of HIV seropositivity is acceptable
• •Diagnosis of untreated Hodgkin lymphoma and participation in the parent protocol SWOG-S0816, "A Phase II Trial of Response Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging."
• •PATIENT CHARACTERISTICS:
• •No psychosocial conditions that would prevent study compliance and follow-up, as determined by the principal investigator
• •Willing to provide serial blood samples
• •PRIOR CONCURRENT THERAPY:
• •See Disease Characteristics